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Abstract
The safe upper limit for inclusion of vitamin A in complete diets for growing dogs is uncertain, with the result that current recommen-
dations range from 5.24 to 104.80 mmol retinol (5000 to 100 000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable energy (ME). The aim
of the present study was to determine the effect of feeding four concentrations of vitamin A to puppies from weaning until 1 year of
age. A total of forty-nine puppies, of two breeds, Labrador Retriever and Miniature Schnauzer, were randomly assigned to one of four treat-
ment groups. Following weaning at 8 weeks of age, puppies were fed a complete food supplemented with retinyl acetate diluted in veg-
etable oil and fed at 1 ml oil/100 g diet to achieve an intake of 5·24, 13·10, 78·60 and 104·80 mmol retinol (5000, 12 500, 75 000 and
100 000 IU vitamin A)/4184 kJ (1000 kcal) ME. Fasted blood and urine samples were collected at 8, 10, 12, 14, 16, 20, 26, 36 and 52
weeks of age and analysed for markers of vitamin A metabolism and markers of safety including haematological and biochemical variables,
bone-specific alkaline phosphatase, cross-linked carboxyterminal telopeptides of type I collagen and dual-energy X-ray absorptiometry.
Clinical examinations were conducted every 4 weeks. Data were analysed by means of a mixed model analysis with Bonferroni corrections
for multiple endpoints. There was no effect of vitamin A concentration on any of the parameters, with the exception of total serum retinyl
esters, and no effect of dose on the number, type and duration of adverse events. We therefore propose that 104·80 mmol retinol
(100 000 IU vitamin A)/4184 kJ (1000 kcal) is a suitable safe upper limit for use in the formulation of diets designed for puppy growth.
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Vitamin A is an essential fat-soluble vitamin that has
functions supporting vision, bone growth, reproduction, cellu-
lar differentiation and immune response in dogs(1). The dog,
unlike non-carnivorous species such as humans or rodents,
transports vitamin A in the plasma predominantly in the
form of retinyl esters, in both adequate and vitamin
A-deprived states(2). In human subjects, retinyl esters are
only detected in the plasma in cases of intoxication or follow-
ing a vitamin A-rich meal(3). The concentrations of retinol
found in dog serum are unaffected by dietary vitamin A
intake, whereas the concentrations of serum retinyl esters
have been shown to parallel the concentrations of vitamin A
in the diet(3). In the dog, excess vitamin A is stored in
esterified form in lipid droplets contained within the hepatic
stellate cells as well as the kidneys(4). In addition to the unu-
sual mechanism of vitamin A transport, dogs, unlike
humans(5), excrete vitamin A in the urine(6) as both retinol
and retinyl esters(7).
As a result of the species differences in metabolism and
excretion, data from other species cannot be used to establish
a dietary safe upper limit for retinol inclusion in the diets of
growing dogs. Some studies in dogs, however, do exist. In
growing dogs (10–12 months of age), prolonged activated
prothrombin time, although not to levels outwith the
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reference range, and elevated retinol binding protein con-
centrations have been reported following feeding a diet
containing 131·00 mmol retinol (125 000 IU vitamin A)/
4184 kJ (1000 kcal) metabolisable energy (ME) for a period
of 26 weeks potentially resulting from an interaction with vita-
min K(1). Exceptionally high dietary intakes (.576·42 mmol
retinol (550 000 IU vitamin A)/4184 kJ (1000 kcal) ME) were
associated with severe side effects including reduced energy
intake, reduced growth rates, pain responses in the carpal
and tarsal joints as well as abnormal bone development and
premature closure of the epiphyseal plate(8–10). These adverse
effects are potentially a result of interactions with vitamin D, as
one study reported a reduction in the severity of effects when
retinol was co-administered with vitamins D and E(11). Much
lower concentrations (10·48 mmol retinol (10 000 IU vitamin
A) kg/body weight) fed to three Cocker Spaniels from wean-
ing to 10 months of age had no apparent adverse effects(12).
The lack of published studies involving retinol concen-
trations above 10·48 mmol retinol (10 000 IU vitamin A)/kg
body weight that have not observed adverse effects may
explain the disparity in recommendations among key nutrition
authorities. The National Research Council(13) recommends a
safe upper limit of 13·10 mmol retinol (12 500 IU vitamin A)/
4184 kJ (1000 kcal) for growing dogs, the American Associ-
ation of Feed Control Officials(14) recommends 74·86 mmol
retinol (71 429 IU vitamin A)/4184 kJ (1000 kcal) and the Fed-
eration Europe´enne de l’Industrie des Ailments pour Animaux
Familiers (FEDIAF)(15) recommends 104·80 mmol retinol
(10 000 IU vitamin A)/4184 kJ (1000 kcal). The purpose of
the present study was to examine the effect on puppies of
feeding four concentrations of vitamin A from weaning until
12 months of age. The hypothesis tested was that feeding diet-
ary retinol concentrations up to 104·80 mmol retinol (10 000 IU
vitamin A)/4184 kJ (1000 kcal) to puppies during growth does
not result in a statistically significant change in biomarkers
associated with health.
Experimental methods
The research protocol was evaluated and approved by theWAL-
THAMw Internal Ethics Committee. The study was a random-
ised, blinded, parallel design. A total of forty-nine
puppies, from eight litters, born at the WALTHAM Centre for
Pet Nutrition were entered into the study. The puppies were
of two breeds, Labrador Retrievers (LR) and Miniature Schnau-
zers (MS). Dogs were housed in litter groups with their mother
until 8 weeks of age and subsequently in pairs, in purpose-
built, environmentally enriched kennels with free access to out-
door areas. The puppies could interact with other dogs in pad-
dock groups, and all puppies participated daily in supervised
group and individual exercise, training and socialisation. The
puppies were habituated to all procedures from 4 weeks of age.
Diet and feeding
The base diet was a standard dry commercial recipe (Perfect
Fit Junior; Mars GmbH) compliant with FEDIAF 2008 rec-
ommendations(15) for growth and reproduction (Table 1).
For each group, ten batches of the diet were used throughout
the study. The predicted ME content of the diet was calculated
according to the National Research Council(13).
The maternal bitch was fed the base diet throughout lacta-
tion until the puppies were fully weaned to the base diet
at 6 weeks of age. For 7 d following weaning (week 6–7),
the puppies were group fed the base diet three times daily.
For the following 7 d (week 7–8), the puppies were indivi-
dually fed the base diet for three, 1 h periods daily. Feeding
amounts were calculated from amounts consumed during
the previous week and adjusted weekly for the remainder of
the study with the aim of maintaining puppies on standard
growth curves with ideal body condition scores(16,17). At
8 weeks of age, puppies were randomised within litter, to
one of four dietary concentrations of vitamin A, namely:
group A 5·24 mmol retinol (5000 IU vitamin A)/4184kJ
Table 1. Nutrient composition of the base diet*
(Mean values and standard deviations, n 10 batches of diet)
Nutrient Mean (units/kg) SD
PME (kJ) 16 640 582
Protein (g) 302 6
Fat (g) 169 4
Ash (g) 69 3
N-free extract (g) 364 20
Crude fibre (g) 23 17
Linoleic acid (g) 25·0 0·4
a-Linolenic acid (g) 1·7 0·1
EPA and DHA (g) 0·9 0·1
Ca (g) 13·1 1·1
P (g) 9·2 0·7
Ca:P 1·4 0·1
Na (g) 5·4 0·7
K (g) 6·0 0·9
Mg (g) 0·86 0·1
Fe (mg) 126 14
Cu (mg) 12 2
Mn (mg) 88 10
Zn (mg) 142 34
I (mg) 1·3 0·3
Se (mg) 360 130
Chloride (g) 1·1 0·1
Retinol (mg) 5870 1047
Cholecalciferol (mg) 39·5 7·6
a-Tocopherol (mg) 529 204
Thiamin (mg) 2·5 0·6
Riboflavin (mg) 20·7 5·4
Niacin (mg) 139·4 44·4
Pyridoxine (mg) 10·0 0·8
Pantothenic acid (mg) 61 25
Folic acid (mg) 1·12 0·8
Cobalamin (mg) 0·13 0·1
Choline (mg) 1222 689
Arg (g) 17·6 0·2
His (g) 5·7 0·5
Ile (g) 10·3 0·1
Leu (g) 24·1 2·5
Lys (g) 13·3 0·94
Met (g) 5·6 0·3
Met þ cystine (g) 9·5 0·4
Phe (g) 9·5 0·8
Phe þ Tyr (g) 21·7 2·7
Thr (g) 9·1 0·4
Val (g) 11·0 0·9
PME, predicted metabolisable energy.
* PME calculated according to the National Research Council (13).

















(1000kcal) ME; group B 13·10 mmol retinol (12 500 IU vitamin
A)/4184 kJ (1000 kcal) ME; group C 78·60 mmol retinol (75 000
IU vitamin A)/4184 kJ (1000 kcal) ME; group D 104·80 mmol
retinol (100 000 IU vitamin A)/4184 kJ (1000 kcal) ME. For
the following 18 weeks (week 8–26), the puppies were
offered their respective diet for a period of 45 min at 08.30,
12.30 and 15.30 hours. For the final 26 weeks of study
(week 26–52), the puppies were offered their daily ration in
two meals at 08.30 and 15.30 hours. Puppies were given
free access to drinking-water at all times.
Vitamin A supplementation
The base diet was supplemented to achieve the required level of
vitamin A by the addition of retinyl acetate (DSM Nutritional
Products Limited) diluted to the required concentration in
vegetable oil. Stock solutions were prepared weekly for each
group according to the manufacturer’s instructions and were
refrigerated in light-proof bottles under N2 until required.
Individual supplements were prepared in 1ml syringes from the
stock solution and kept refrigerated in light-proof containers
before being added to the diet at a ratio of 1 ml supplement/
100 g of diet immediately before feeding and mixed thoroughly.
A 1ml aliquot of each stock solution was analysed within 48h of
the stock solution preparation for retinyl acetate concentrations
using modified gradient reversed-phase HPLC analysis(3) to
allow for the calculation of actual vitamin A intake.
Measurement of food intake and body weight
Food intake was recorded immediately following each meal as
the difference between the mass of food presented and the
mass of food returned (Sartorius UK Limited). Body weight
was recorded weekly using calibrated scales (Sartorius UK
Limited) immediately before the first meal of the day. Although
not fully validated in puppies, the body condition score was
conducted weekly (WALTHAM S.H.A.P.E. guide(17)), imme-
diately before feeding.
Blood sample analysis
A 2·8 ml blood sample was taken from a jugular vein following
an overnight fast of at least 16 h at week 8, before dietary
supplementation, and at weeks 10, 12, 14, 16, 20, 26, 35
and 52. Blood samples were collected into a single syringe
and immediately distributed between tubes containing either
tripotassium EDTA, lithium heparin or no anticoagulant.
For biochemical analysis, 0·5 ml of blood were deposited
into a tube containing lithium heparin as an anticoagulant.
The tube was mixed gently for 10 s before being stored on
ice for a maximum of 30 min. The sample was then centri-
fuged at 2000 g for 10 min at 4 8C. The resultant plasma was
pipetted into an AU400 sample cup before automated colori-
metric analysis (Olympus AU400; Olympus, Inc.) for concen-
trations of total protein, albumin, alkaline phosphatase,
aspartate aminotransferase, alanine aminotransferase, total
cholesterol, urea, creatinine, Ca, phosphate, TAG, glutamate
dehydrogenase and total bile acids.
For haematological analysis, a 0·2 ml blood sample was
deposited into a tube containing tripotassium EDTA as an
anticoagulant. This was gently mixed on a roller for 10 min
at room temperature before automated analysis for leucocyte
count, erythrocyte count, Hb concentration, haematocrit, pla-
telet count, mean corpuscular volume, mean corpuscular Hb,
mean corpuscular Hb concentration, number and percentage
of lymphocytes, monocytes and granulocytes (ABC, Scil Vet).
For retinol and retinyl esters, the remaining 2·1 ml blood
sample was deposited into a light-proof tube containing no
anticoagulant. The tube was placed in an upright position for
90 min at room temperature, to allow clot formation, before
centrifugation at 2000g for 10 min at room temperature. The
resultant serum was pipetted into 1·5 ml light-proof Eppendorf
tubes, frozen at280 8C, shipped overnight on ice and stored at
280 8C for a maximum of 30 d before analysis using modified
gradient reversed-phase HPLC analysis, as described else-
where(3), to determine the concentrations of retinol, retinyl
oleate, retinyl stearate and retinyl palmitate. The total retinyl
ester concentration was calculated as the sum of retinyl
oleate, retinyl stearate and retinyl palmitate concentrations.
For bone turnover assessment, the remainder of the serum
sample used for retinol and retinyl ester analyses was used to
measure cross-linked carboxyterminal telopeptides of type I
collagen (CTx) concentrations, as an indicator of bone resorp-
tion, using a commercial ELISA (Serum CrossLaps ELISA; IDS).
Serum bone-specific alkaline phosphatase activity, as an indi-
cator of osteoblastic activity, was measured with a commercial
ELISA assay (Osteomedical).
Urine samples
At 1 d before blood sampling, a 1·2 ml urine sample was
collected following a 16 h fast between the hours of 08.00
and 10.00 by a free-catch method. If a urine sample could
not be obtained on the first day of sampling, the process
was repeated on the following day before blood sampling.
The samples were placed in light-proof Eppendorf tubes,
and then stored, shipped and analysed for retinol and retinyl
esters as described above.
Bone mineral density and bone mineral content
Bone mineral density (BMD) was assessed at 26 and 52 weeks of
age by means of dual-energy X-ray absorptiometry (DXA, total
body software package, Lunar Hologic QDR-1000W; GE Health-
care). Dogs were sedated following a minimum 16 h fast, with
a combination of Torbugesic (0·3 mg/kg; Pfizer Animal
Health), Medetomidine (MS: 20mg/kg, LR: 5mg/kg; Pfizer
Animal Health) and Midazolam (MS: 0·25 mg/kg, LR: 0·20 mg/
kg; Roche Limited), and reversed with Atipamezole (0·1 mg/
kg; Pfizer Animal Health).
Clinical examinations and adverse event reporting
The puppies underwent physical examination before the start of
the trial andevery4weeks thereafter. Particular attentionwaspaid
to signs of joint or muscle pain. In addition, any illness or injury

















between the examinations that required veterinary attention was
considered an adverse event. Adverse events were classified into
ten categories, namely: poor faeces quality, vomiting, foreign
body ingestion, lameness, accident/injury, skin conditions, eye
conditions, ear conditions, dental conditions and urinary con-
ditions. On each occasion, the type and duration of treatment
were recorded. Any blood parameters outside of the puppy refer-
ence range(18) were referred to the veterinarian for investigation
and re-tests were conducted within 24h and repeated as required
for diagnosis. The veterinarian was blinded to the dietary
treatment groups.
Data analysis and statistics
The primary outcome variable was total serum retinyl ester
concentration. Retinyl ester concentration was selected as
the primary outcome variable to demonstrate a biological
impact of feeding various levels of retinol to growing dogs.
The study was powered at 90 % to detect differences between
the groups based on a previously described log-linear
relationship between dietary vitamin A intake and serum reti-
nyl ester concentration(3). The power calculation determined a
minimum of nine dogs per group; this was increased to eleven
to account for potentially greater variability in puppies com-
pared with adult dogs. Following the conclusion of the
study, post hoc power analyses were conducted on each of
the safety biomarkers to determine whether there was suffi-
cient power (. 80 %) to detect a clinically relevant effect
size with the variation associated with the dataset. A clinically
relevant change was defined as a change from the mean of
each variable to a mean outside the reference range(18).
Data were analysed by means of linear mixed model anal-
ysis including the fixed terms sample number, sex, breed
and dietary group, and also the baseline measurement of the
variable being modelled. The model included the random
terms dog and litter (to take account of possible similarities
between littermates), with a correlation between successive
samples (within an individual dog) accounted for via use
Table 2. Population demographics of dogs completing the trial*
Group A Group B Group C Group D
n 15 11 11 11
Breed
MS 8 6 6 5
LR 7 5 6 6
Sex
Male 8 5 6 6
Female 7 6 6 5
MS, Miniature Schnauzer; LR, Labrador Retriever.
* Group A, 5·24 mmol retinol (5000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable
energy (ME); group B, 13·10 mmol retinol (12 500 IU vitamin A)/4184 kJ (1000 kcal)
ME; group C, 78·60 mmol retinol (75 000 IU vitamin A)/4184 kJ (1000 kcal) ME;


































30 32 34 36 38 40 42 44 46 48 50 52
Fig. 1. Actual vitamin A intake of puppies from 8 to 52 weeks of age. Values are means, with 95 % CI represented by vertical bars. Mean values were significantly
different between the groups (P,0·05). Group A ( ), 5·24 mmol retinol (5000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable energy (ME); group B ( ),
13·10 mmol retinol (12 500 IU vitamin A)/4184 kJ (1000 kcal) ME; group C ( ), 78·60 mmol retinol (75 000 IU vitamin A)/4184 kJ (1000 kcal) ME; group D
( ), 104·80 mmol retinol (100 000 IU vitamin A)/4184 kJ (1000 kcal) ME.

















of an appropriate correlation structure (determined using
graphical methods of residuals from a model with identity
correlation structure). Where necessary, data were loge trans-
formed to improve the distribution of the data, as assessed
by residual plots. Non-significant terms were removed from
the model. Data analyses were performed using R.2.10.1
(R Foundation for Statistical Computing).
All primary and secondary endpoints were separately sub-
jected toBonferroni correction toaccount for thepresenceofmul-
tiple endpoints; the overall significance level used was 0·05. Data
are presented asmeans with their 95% CIunless otherwise stated,
and P values are reported as Bonferroni-corrected P values.
Results
Population demographics
The study population demographics are described in Table 2. A
total of forty-eight dogs completed the study. A total of forty-
eight dogs completed the study. A single LR, allocated to
group C, was removed from the study at 9 months of age follow-
ing diagnosis of a congenital kidney defect. All data from this
dog were removed from the analysis. There were no differences
in breed or sex distribution between the groups.
Dietary intake and growth
There were no significant differences in energy intake on a per
kg body weight or per kg metabolic body-weight basis
between the groups. As intended, there were significant differ-
ences in dietary vitamin A intake between the groups
(P¼0·0001). When expressed on a per kg body-weight
basis (P¼0·0001) and on a per kg metabolic body-weight
basis (P¼0·0001) (Fig. 1), both vitamin A and energy intake
significantly decreased over time with maximal intake
recorded at week 8. Body weight significantly increased in
all groups with time (P¼0·0001; Fig. 2), and all dogs main-
tained an ideal body condition score (score D) throughout
the trial. There were no significant differences in body
weight between the groups at any time point (P¼1·00) nor
any significant differences in the rate of growth (P¼1·00).
There was a significant effect of breed, with LR having signifi-






















Fig. 2. Body weight of two breeds of puppies from 8 to 52 weeks of age. Values are means, with 95 % CI represented by vertical bars. Mean values were significantly
different between the groups (P,0·05). Group A, 5.24 mmol retinol (5000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable energy (ME); group B, 13.10 mmol retinol
(12 500 IU vitamin A)/4184 kJ (1000 kcal) ME; group C, 78.60 mmol retinol (75 000 IU vitamin A)/4184 kJ (1000 kcal) ME; group D, 104.80 mmol retinol (100 000 IU vita-
min A)/4184 kJ (1000 kcal) ME. , Labrador Retriever (LR) group A; , LR group B; , LR group C; , LR group D; , Miniature Schnauzer (MS)
group A; , MS group B; , MS group C; , MS group D.


















There were no significant differences in any of the haema-
tological or biochemical parameters between the groups at
any time point. However, some variables (Table 3), namely
erythrocyte count, mean corpuscular volume, mean corpuscu-
lar Hb, mean corpuscular Hb concentration, mean platelet
volume, number of monocytes, number of granulocytes,
alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase and cholesterol, showed statistically significant
changes with age. Bone-specific alkaline phosphatase signifi-
cantly decreased (P¼0·0001) and cross-laps (CTx) significantly
increased (P¼0·0001) with age. There were no significant
differences, however, in the concentrations of bone-specific
alkaline phosphatase (P¼1·00) or CTx (P¼1·00) between any
of the groups at any time point.
Table 3. Change in clinical chemistry parameters with age and treatment group*
(Mean values with their 95 % confidence intervals)
Group A† Group B‡ Group C§ Group Dk
Age (weeks) Mean 95 % CI Mean 95 % CI Mean 95 % CI Mean 95 % CI P{
Protein (g/l) 8 48·3 47·2, 49·4 49·5 47·7, 51·3 48·3 46·4, 50·1 47·9 46·3, 49·5
26 55·7 53·9, 57·5 55·8 53·3, 58·3 55·7 54·0, 57·5 55·5 53·8, 57·2 0·526
52 54·9 53·1, 56·6 57·3 55·3, 59·3 58·0 56·5, 59·5 57·1 55·4, 58·8
Albumin (g/l) 8 24·9 23·7, 26·1 25·1 22·9, 27·2 24·7 22·8, 26·6 24·0 22·3, 25·7
26 29·6 28·9, 30·3 29·6 28·3, 31·0 29·1 28·2, 30·0 29·2 28·1, 30·2 0·379
52 28·5 27·1, 29·8 29·8 28·5, 31·1 30·3 29·2, 31·4 29·6 28·4, 30·92
Phosphate (mmol/l) 8 2·72 2·63, 2·8 2·69 2·62, 2·75 2·71 2·58, 2·84 2·72 2·61, 2·83
26 2·29 2·12, 2·45 2·24 2·02, 2·47 2·24 2·06, 2·43 2·31 2·13, 2·48 0·869
52 1·64 1·54, 1·75 1·63 1·52, 1·75 1·72 1·58, 1·86 1·62 1·5, 1·75
ALP (U/l) 8 432 405, 460 447 396, 499 448 403, 492 405 348, 462
26 221 187, 254 232 210, 255 247 213, 281 222 189, 256 0·780
52 104 76, 132 103 83, 124 109 86, 132 109 82, 137
ALT (U/l) 8 25·6 22·5, 28·7 25·0 20·9, 29·2 23·8 20·7, 27·0 23·9 19·4, 28·4
26 37·8 34·5, 41·1 42·7 35·1, 50·4 35·1 31·7, 38·5 41·3 34·8, 47·8 0·862
52 48·5 34·5, 62·6 45·7 39·0, 52·4 39·0 34·9, 43·1 63·1 33·7, 92·6
AST (U/l) 8 24·9 21·5, 28·3 23·3 20·7, 25·9 24·9 21·9, 27·9 24·6 22·0, 27·3
26 30·5 27·4, 33·6 29·2 25·6, 32·9 29·3 25·8, 32·8 30·7 25·2, 36·1 0·695
52 30·0 27·0, 33·0 29·3 25·6, 32·9 28·1 25·8, 30·5 27·5 23·6, 31·4
Ca (mmol/l) 8 2·84 2·80, 2·88 2·84 2·79, 2·89 2·82 2·76, 2·87 2·83 2·79, 2·87
26 2·75 2·71, 2·80 2·79 2·75, 2·84 2·77 2·72, 2·82 2·77 2·72, 2·82 0·535
52 2·59 2·55, 2·63 2·62 2·59, 2·64 2·65 2·60, 2·71 2·60 2·56, 2·64
Cholesterol (mmol/l) 8 5·18 4·78, 5·58 5·02 4·62, 5·42 4·87 4·45, 5·29 4·96 4·58, 5·33
26 7·00 6·33, 7·67 6·84 6·15, 7·52 6·53 5·86, 7·2 6·79 6·25, 7·32 0·974
52 5·86 5·21, 6·51 6·11 5·54, 6·67 5·86 5·27, 6·46 6·14 5·61, 6·66
Urea (mmol/l) 8 2·29 2·03, 2·55 2·39 2·04, 2·75 2·56 2·19, 2·94 2·17 1·97, 2·37
26 4·96 4·49, 5·43 4·91 4·44, 5·39 4·81 4·47, 5·13 4·57 4·19, 4·94 0·135
52 5·74 5·35, 6·13 5·78 5·35, 6·22 6·00 5·35, 6·64 5·44 4·84, 6·04
Creatinine (mmol/l) 8 38·3 36·9, 39·6 38·0 36·3, 39·7 36·5 35·0, 38·0 37·9 36·7, 39·3
26 72·3 68·7, 76·0 70·3 68·2, 72·5 67·7 65·3, 70·2 69·8 65·6, 73·9 0·500
52 83·1 76·4, 89·9 84·9 77·5, 92·2 83·6 77·1, 90·1 82·7 75·3, 90·0
TAG (mmol/l) 8 0·68 0·6, 0·76 0·67 0·6, 0·75 0·62 0·53, 0·71 0·61 0·54, 0·68
26 0·71 0·56, 0·85 1·03 0·45, 1·62 0·72 0·52, 0·91 0·65 0·52, 0·77 0·661
52 0·54 0·46, 0·62 0·59 0·43, 0·74 0·57 0·49, 0·65 0·71 0·55, 0·87
Total bile acids (mmol/l) 8 2·65 1·18, 4·12 3·11 0·33, 5·88 3·65 1·2, 6·11 1·65 1·3, 1·99
26 3·18 1·64, 4·72 5·55 2·77, 8·32 1·30 1·05, 1·56 2·40 0·83, 3·96 0·759
52 4·22 1·22, 7·23 7·03 0·39, 13·66 7·37 1·38, 13·36 2·92 1·53, 4·32
GLDH (U/l) 8 4·67 4·31, 5·04 4·54 4·19, 4·90 4·40 3·87, 4·92 4·62 4·19, 5·06
26 5·23 4·50, 5·95 6·41 4·79, 8·04 4·70 4·12, 5·28 5·41 4·34, 6·48 0·355
52 6·45 3·74, 9·15 5·10 4·02, 6·19 4·85 3·72, 5·98 5·86 3·98, 7·73
bALP (pmol/l) 8 87·9 81·7, 94·1 94·1 78·5, 109·8 88·7 76·7, 100·7 80·0 69·2, 90·8
26 40·7 35·3, 46·1 43·0 38·3, 47·6 44·1 39·1, 49·0 38·3 33·2, 43·3 1·00
52 15·9 12·0, 19·8 15·6 12·3, 18·9 16·3 12·8, 19·9 15·5 11·8, 19·1
CTx (pg/ml) 8 294 250, 338 324 255, 393 289 236, 342 333·1 277, 389
26 646 547, 745 651 544, 759 605 521, 689 595 498, 692 1·00
52 915 740, 1089 915 740, 1088 821 637, 1006 878 647, 1110
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLDH, glutamate dehydrogenase; bALP, bone-specific ALP; CTx, carboxyterm-
inal telopeptides of type I collagen.
* Data were analysed via mixed model.
† 5·24 mmol retinol (5000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable energy (ME).
‡ 13·10 mmol retinol (12 500 IU vitamin A)/4184 kJ (1000 kcal) ME.
§ 78·60 mmol retinol (75 000 IU vitamin A)/4184 kJ (1000 kcal) ME.
k104·80 mmol retinol (100 000 IU vitamin A)/4184 kJ (1000 kcal) ME.
{Significance of difference between the treatment groups (Bonferroni corrected).

















Both serum retinol (P¼0·0001) and serum total retinyl ester
concentrations (P¼0·015) increased with time. There was no
significant difference in serum retinol concentration between
the groups (P¼1·00), whereas total retinyl ester concen-
trations were significantly different (Fig. 3) between each
group and all the other groups at all time points (P¼0·0001)
with the exception of baseline (week 8).
Urine sample analysis
Excretion of retinol and retinyl esters in the urine was negli-
gible up to 26 weeks of age and was not consistently detected
until 35 weeks of age (Fig. 4). There were no significant differ-
ences in the time to excretion of retinol (P¼1·00) or retinyl
esters (P¼1·00) between the groups nor were there differ-
ences between the groups in concentrations of retinol
(P¼1·00) and retinyl esters (P¼1·00) excreted at weeks 35
and 52.
Bone mineral density and bone mineral content
There was no significant effect of dietary vitamin A concen-
tration on BMD (P¼0·137) or bone mineral content (P¼0·936)
as assessed by DXA (Table 4). There was a significant effect of
breed, with LR having greater BMD (P¼0·0001) and bone min-
eral content (P¼0·0020) than MS at both time points.
Clinical examination and adverse events
There were no significant differences between the treatment
groups in the number and type of adverse events reported.
Poor faeces quality was the most commonly reported adverse
event (n 22), with twenty individual dogs affected. All cases
were resolved within 3 d. In LR, two cases of lameness without
apparent cause were observed, one in group A and one in
group C; both cases were resolved following treatment in





































Fig. 3. Change in total serum retinyl ester concentrations with age in growing puppies. Values are means, with 95 % CI represented by vertical bars. Mean values
were significantly different between the groups (P,0·05). Group A ( ), 5.24 mmol retinol (5000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable energy (ME);
group B ( ), 13.10 mmol retinol (12 500 IU vitamin A)/4184 kJ (1000 kcal) ME; group C ( ), 78.60 mmol retinol (75 000 IU vitamin A)/4184 kJ (1000 kcal)
ME; group D ( ), 104.80 mmol retinol (100 000 IU vitamin A)/4184 kJ (1000 kcal) ME.


















Thehypothesis testedwas that feedingdietaryvitaminAat concen-
trations up to 104·80 mmol retinol (100 000 IU vitamin A)/4184kJ
(1000kcal) ME to puppies during growth would not result in
any significant changes in biomarkers associated with health.
No significant differences were found in any of the bio-
markers of health including biochemical markers or haemato-
logical parameters. Previous data from human subjects and
other animal species indicate that excess vitamin A is associ-
ated with a stimulation of bone resorption and an inhibition
of bone formation leading to a reduction in BMD potentially
resulting from interactions between vitamins A and D(11). No
significant differences were found in the biomarkers of these
processes namely bone-specific alkaline phosphatase and
CTx, and there was no significant effect of dose on either
BMD or bone mineral content as assessed by DXA. There
are no specific studies examining the interaction between vita-
mins A and D in the dog. In rats and broiler chickens,
biochemical studies have suggested an antagonism between
vitamins A and D at the receptor level(19,20) as well as an
interaction with Ca-regulating hormones such as parathyroid
hormone(21). There was no significant effect of dietary vitamin
A concentration on plasma Ca or P levels, which suggests
that vitamin D deficiency did not occur, although the levels
of cholecalciferol in the diet were approximately three times
the FEDIAF’s recommended allowance(15). Further studies
are required to understand whether there is an interaction
between vitamins A and D in the dog and if so, at which
dietary concentrations an interaction occurs.
Feeding high levels of retinol has also been shown to
prolong activated prothrombin time in the dog, although not
outwith the reference range(1). This is potentially due to
the interactions with vitamin K. Activated prothrombin time
was not directly measured in the present study; however,
no signs of clinical vitamin K deficiency such as increased






































Fig. 4. Total urinary retinyl ester excretion. Values are means, with 95 % CI represented by vertical bars. Mean values were significantly different between the
groups (P,0·05). Group A ( ), 5.24 mmol retinol (5000 IU vitamin A)/4184 kJ (1000 kcal) metabolisable energy (ME); group B ( ), 13.10 mmol retinol
(12 500 IU vitamin A)/4184 kJ (1000 kcal) ME; group C ( ), 78.60 mmol retinol (75 000 IU vitamin A)/4184 kJ (1000 kcal) ME; group D ( ), 104.80 mmol reti-
nol (100 000 IU vitamin A)/4184 kJ (1000 kcal) ME.

















Unlike previous studies in young dogs fed much higher
dietary concentrations of vitamin A (314·41 mmol retinol
(300 000 IU vitamin A)/kg body weight)(9), there were no
differences in the rate of growth, energy intake or body
weight at any time between the groups. No differences in
the number, type or duration of adverse effects were observed
and those that were observed could not be attributed to the
variation in dietary vitamin A concentration. The present
study was limited to the first 52 weeks of life and suggests
that dietary vitamin A at the concentrations tested is safe to
feed during this growth phase.
As with observations in adult dogs(3), increased dietary
retinol concentration was associated with increased serum
retinyl ester concentrations (Fig. 3) but not with serum retinol
concentrations. Until 26 weeks of age, the concentrations of
retinol observed in the present study were significantly
lower than concentrations previously reported in adult
dogs(3). This observation is consistent with previous reports
of increasing concentrations of retinol in the serum of
maned wolf cubs with age that reached adult concentrations
at approximately 5 months of age(22).
Unlike observations in adult dogs, however, the puppies
excreted negligible amounts of retinol and retinol esters in
the urine (Fig. 4). The excretion of these compounds appears
to be age dependent rather than as a result of storage capacity,
as there was no difference between the groups in time to
excretion or total amounts of the compounds excreted despite
a 20-fold difference in the doses fed. Previous research in
adult dogs(4) suggested that excess dietary vitamin A is
stored in the stellate cells of the liver but in the present
study, we were unable to confirm whether, and how, vitamin
A was stored in the liver of puppies since this would have
required serial liver biopsies to determine the effect of time.
Liver biopsies were not included in the protocol due to the
host institution’s ethical policy. The lack of retinol and retinyl
ester excretion in the urine until 35 weeks of age certainly
requires further investigation. Examination of the proteins
known to be involved in retinyl ester transport and excretion
such as retinal-binding protein and Tamm–Horsfall-like
protein(23) may provide an insight into the mechanism
behind this age-dependent effect.
In summary, no adverse effects were detected with feeding
dietary vitamin A at concentrations up to 104·80 mmol retinol
(10 000 IU vitamin A)/4184 kJ (1000 kcal) to MS and LR pup-
pies from 8 weeks to 12 months of age. We therefore propose
that 100 000 IU vitamin A/4184 kJ (1000 kcal) is a suitable safe
upper limit for use in the formulation of diets designed for
puppy growth.
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